Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit (Firefly Sheffield)

August 2, 2019 updated by: GE Healthcare

Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit

This study investigates a novel magnetic resonance imaging (MRI) system designed by GEHC for imaging viable neonate and infant populations. This MR system has a smaller size and design features that may make it more feasible to locate the system in close proximity to care areas for neonates (birth - 1 month) and infants (>1 month to two years), such as clinical neonatal intensive care units (NICUs) and other infant and neonatal care departments.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

This study investigates a novel magnetic resonance imaging (MRI) system designed by GEHC for imaging viable neonate and infant populations. This MR system has a smaller size and design features that may make it more feasible to locate the system in close proximity to care areas for neonates (birth - 1 month) and infants (>1 month to two years), such as clinical neonatal intensive care units (NICUs) and other infant and neonatal care departments.

This is a two-phase prospective clinical study evaluating the performance and safety of the investigational MRI device for neonates and infants, including:

  • Phase 1 - Initial feasibility assessment and optimization study (Phase 1) which may include hardware and software modifications. These studies are guided by a series of MR scanning procedures defined in sequential Sponsor-provided MR Procedure Documents
  • Phase 2 - Controlled image and data collection study based on Phase 1 results, in which optimized scan procedure(s) according to MR Procedure Document(s) will be provided at the start of Phase 2 scanning and a fixed hardware and integrated software configuration will be applied for all subjects.

Investigator feedback on scanning conducted under each MR Procedure Document will be documented. Because the device is intended for use in viable neonate and infant populations, clinical data are required that cannot be conducted in any other populations or simulated on non-human models. Clinical images and associated data as well as assessments of image quality, workflow, and usability will be collected.

Images, associated image data, and subject data collected in both phases of this study may be used for future engineering development and activities that support MR product development, including Sponsor-authorized scientific and marketing activities. Summary evaluation of safety and performance from Phase 1 and Phase 2 may be used in support of regulatory submission, including filings for European CE mark.

Study Type

Interventional

Enrollment (Actual)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Sheffield, United Kingdom, S10 2JF
        • University of Sheffield, Royal Hallamshire Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 minute to 2 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Currently admitted for treatment or observation at the investigational site at the time of enrolment;
  • weight range less than 5.0 kg (<5.0 kg ) and more than 0.5 kg (>0.5 kg );
  • Viable neonates (birth to 1 month of age) or infants (>1 month to two years of age);
  • Able to safely undergo an MRI scan, as determined by medically qualified personnel;
  • Have parent(s), guardian(s), or legally authorized representative(s) willing and able to provide written informed consent for the subject's participation;
  • Are of appropriate size and shape to fit into the bore of the magnet, inclusive of all monitoring equipment, if any, necessary for the subject's routine clinical care based on standard of care measurement methods, in accordance with site policies :

    1. Maximum width (shoulder-to-shoulder measurement) less than eighteen (18 cm).
    2. Maximum length (head-to-foot measurement) less than sixty (60) cm.

Exclusion Criteria:

  • Have parent(s), guardian(s), or legally authorized representative(s) that require that they accompany the subject into the MR environment that have contraindications to the MR environment or would otherwise be put at undue risk or discomfort, as determined by medically qualified personnel;
  • Have any ferrous or electrical items or non-removable medical devices that are not compatible with MR scanning (including devices labelled as MR Unsafe, MR conditional for which the scanning conditions are not met, or without MR safety labelling that does not satisfy site MR safety requirements) that may pose hazards in the MR scanning or MR environment, in the opinion of the Principal Investigator or medically qualified personnel in accordance with the site's MR Safety policy;
  • Have any contraindications or could otherwise be expected to experience detrimental effects to safety, well-being, or medical care, as determined by the Principal Investigator or medically qualified personnel in accordance with the site's MR Safety policy;
  • Require any scheduled standard of care procedures that are expected to be adversely impacted by participation in this study, in the opinion of the principal investigator or medically qualified personnel; and
  • Have been previously enrolled AND undergone any study procedures under the current study protocol (i.e. the same subject cannot undergo study procedures, including swaddling and/or MR scanning, more than once).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: 3.0 T Neonatal MRI scanner
All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
eligible subjects will undergo neonatal MRI scan procedure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Image Diagnostic Quality for Phase 1
Time Frame: 1 Day
Number of subject whose images were rated as Evaluable.
1 Day
Number of Participants Who Experienced an Adverse Event in Phase 1
Time Frame: 1 Day
Safety will be assessed based on the number of Adverse Events in Phase 1.
1 Day
Image Diagnostic Quality for Phase 2
Time Frame: 1 Day
Number of subject whose images were rated as Evaluable.
1 Day
Number of Participants Who Experienced an Adverse Event in Phase 2
Time Frame: 1 Day
Safety will be assessed based on the number of Adverse Events in Phase 2.
1 Day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Summary of Image Quality and Assessment for Phase 1
Time Frame: 1 Day
Scores range from 1-Very Poor image quality to 5-Excellent image quality.
1 Day
Summary of Image Quality and Assessments for Phase 2
Time Frame: 1 Day
Scores range from 1-Very Poor image quality to 5-Excellent image quality.
1 Day
Per Subject Workflow and Transport Information
Time Frame: 1 Day
Summary of means and standard deviations.
1 Day
Overall Experience With the Neonatal MR Scanner Device Summary
Time Frame: 1 Day

User survey results on a scale from 1 to 5, where 1 = strongly disagree and 5 = strongly agree.

Question 1. I think that I would like to use this system frequently Question 2. I found the system unnecessarily complex Question 3. I thought the system was easy to use Question 4. I think that I would need support from a technician to be able to use this system Question 5. I found the various functions in this system were well integrated Question 6. I thought there was too much inconsistency in this system Question 7. I think that most people would learn to use this system very quickly Question 8. I found the system very cumbersome to use Question 9. I felt very confident using the system Question 10. I needed to learn a lot of things before I could get going with this system Question 11. I feel confident this system will meet my patient's needs Question 12. How likely is it that you would recommend this system to other professionals in your field?

1 Day
Bi-polar Product Description Scale
Time Frame: 1 Day
A measure of bi-polar items (opposite items), rated on a scale from 1 to 7. Closer to 1 indicates a measure closer to the first item and closer to 7 indicates a measure closer to the second item.
1 Day
Technical Issues and Malfunctions
Time Frame: 1 Day
Number and type of technical issues and device malfunctions
1 Day
Subject Change in Temperature
Time Frame: 1 Day
1 Day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Paul Griffiths, MD, PhD, University of Sheffield

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 22, 2016

Primary Completion (Actual)

August 20, 2017

Study Completion (Actual)

April 20, 2018

Study Registration Dates

First Submitted

May 19, 2016

First Submitted That Met QC Criteria

May 27, 2016

First Posted (Estimate)

May 30, 2016

Study Record Updates

Last Update Posted (Actual)

September 13, 2019

Last Update Submitted That Met QC Criteria

August 2, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 114-2014-GES-0035

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe